Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

NCT07401875 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT07401875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07401875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
March 24, 2026
Completion date
November 30, 2029
Enrollment
35 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hc-7366, kidney cancer, phase 1b, shark